Trial Profile
A Randomized, Double-Blind, Multi-Center, Parallel-Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD (Ethos)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jul 2023
Price :
$35
*
At a glance
- Drugs Budesonide/formoterol/glycopyrrolate (Primary) ; Budesonide/formoterol; Formoterol/glycopyrrolate
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms ETHOS
- Sponsors Pearl Therapeutics
- 24 May 2023 Post-hoc analysis results presented at the 119th International Conference of the American Thoracic Society.
- 09 Nov 2022 Results assessing Budget Impact Analysis of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate for COPD in the Italian Healthcare System presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 24 Oct 2022 According to an AstraZeneca media release, based on the results of this ETHOS and KRONOS studies, the company announced the Canadian availability of Breztri, indicated for the long-term maintenance treatment to reduce exacerbations of chronic obstructive pulmonary disease (COPD) and treat airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema who are not adequately treated by a combination of an ICS/LABA or a combination of a LAMA/LABA.